Stock Taper
Insulet Corporation develops and sells the Omnipod tubeless insulin delivery system and related devices for insulin-dependent diabetes patients worldwide.

The Omnipod 5 is a tubeless, wearable insulin pump that automatically adjusts insulin delivery based on CGM data and can be controlled via a smartphone, offering advanced, automated diabetes management.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | International Omnipod | $699.2M | $781.8M ▲ | $758.5M ▼ | $795.9M ▲ |
![]() | Drug Delivery | $7.1M | $1.9M ▼ | $3.3M ▲ | $5.8M ▲ |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $504.2M | $569.8M ▲ | $518.8M ▼ | $549.9M ▲ |
![]() | NonUS | $202.1M | $214M ▲ | $242.9M ▲ | $251.8M ▲ |
Overall rating: B
| PEER | PRICE | |
|---|---|---|
DXCM | $90.82 | COMPARE |
BIIB | $218.50 | COMPARE |
WAT | $414.69 | COMPARE |
LH | $335.11 | COMPARE |
DGX | $242.76 | COMPARE |
PHG | $26.72 | COMPARE |
WST | $337.47 | COMPARE |
STE | $233.78 | COMPARE |